Stay updated with breaking news from Thierry Andre. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compared with chemotherapy, nivolumab plus ipilimumab reduced the risk of disease progression or death by 79%, but further research is needed to assess overall survival.
First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.
Nivolumab/ipilimumab led to improvement in untreated MSI-H/dMMR disease versus chemo
First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free survival with Opdivo plus Yervoy compared to...
Nivolumab/ipilimumab reduced the risk of disease progression or death vs chemotherapy in previously untreated patients with metastatic colorectal cancer.